Loading…
Evogliptin: First Global Approval
Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent...
Saved in:
| Published in: | Drugs (New York, N.Y.) N.Y.), 2015-11, Vol.75 (17), p.2045-2049 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c372t-f64da8eeb549e61c163eab5d5e775ee2fad06b230432afd94eefcef84c8238453 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c372t-f64da8eeb549e61c163eab5d5e775ee2fad06b230432afd94eefcef84c8238453 |
| container_end_page | 2049 |
| container_issue | 17 |
| container_start_page | 2045 |
| container_title | Drugs (New York, N.Y.) |
| container_volume | 75 |
| creator | McCormack, Paul L. |
| description | Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals. In October 2015, evogliptin received its first global approval in South Korea for blood glucose control in patients with type 2 diabetes mellitus. This article summarizes the milestones in the development of evogliptin leading to this first approval for type 2 diabetes mellitus. |
| doi_str_mv | 10.1007/s40265-015-0496-5 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1733194123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3880080471</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-f64da8eeb549e61c163eab5d5e775ee2fad06b230432afd94eefcef84c8238453</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRbK3-AC9S8eIlurOfWW-ltFUoeNHzskkmJSVNYrYp-O_dkCoieBiWYZ95Z3gIuQb6AJTqRy8oUzKiEEoYFckTMgbQJgIj6SkZUwosUkrpEbnwftu3RppzMgpTArTiY3K7ONSbsmj2RfU0XRat309XZZ24cjprmrY-uPKSnOWu9Hh1fCfkfbl4mz9H69fVy3y2jlKu2T7KlchcjJhIYVBBCoqjS2QmUWuJyHKXUZUwTgVnLs-MQMxTzGORxozHQvIJuR9yw9qPDv3e7gqfYlm6CuvOW9CcgxHAeEDv_qDbumurcF1PaQncxDRQMFBpW3vfYm6btti59tMCtb0_O_izwZ_t_dn-iJtjcpfsMPuZ-BYWADYAPnxVG2x_rf439Quw1njI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1737513980</pqid></control><display><type>article</type><title>Evogliptin: First Global Approval</title><source>Springer Link</source><creator>McCormack, Paul L.</creator><creatorcontrib>McCormack, Paul L.</creatorcontrib><description>Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals. In October 2015, evogliptin received its first global approval in South Korea for blood glucose control in patients with type 2 diabetes mellitus. This article summarizes the milestones in the development of evogliptin leading to this first approval for type 2 diabetes mellitus.</description><identifier>ISSN: 0012-6667</identifier><identifier>EISSN: 1179-1950</identifier><identifier>DOI: 10.1007/s40265-015-0496-5</identifier><identifier>PMID: 26541763</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>AdisInsight Report ; Agreements ; Antigens ; Bioavailability ; Clinical trials ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-Peptidase IV Inhibitors - adverse effects ; Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics ; Dipeptidyl-Peptidase IV Inhibitors - pharmacology ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Drug Approval ; Drug dosages ; Glucagon ; Glucose ; Hormones ; Humans ; Insulin ; Internal Medicine ; Licenses ; Licensing ; Medicine ; Medicine & Public Health ; Pharmacology/Toxicology ; Pharmacotherapy ; Piperazines - adverse effects ; Piperazines - pharmacokinetics ; Piperazines - pharmacology ; Piperazines - therapeutic use ; Plasma ; Polypeptides ; Urine</subject><ispartof>Drugs (New York, N.Y.), 2015-11, Vol.75 (17), p.2045-2049</ispartof><rights>Springer International Publishing Switzerland 2015</rights><rights>Copyright Springer Science & Business Media Nov 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-f64da8eeb549e61c163eab5d5e775ee2fad06b230432afd94eefcef84c8238453</citedby><cites>FETCH-LOGICAL-c372t-f64da8eeb549e61c163eab5d5e775ee2fad06b230432afd94eefcef84c8238453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26541763$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McCormack, Paul L.</creatorcontrib><title>Evogliptin: First Global Approval</title><title>Drugs (New York, N.Y.)</title><addtitle>Drugs</addtitle><addtitle>Drugs</addtitle><description>Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals. In October 2015, evogliptin received its first global approval in South Korea for blood glucose control in patients with type 2 diabetes mellitus. This article summarizes the milestones in the development of evogliptin leading to this first approval for type 2 diabetes mellitus.</description><subject>AdisInsight Report</subject><subject>Agreements</subject><subject>Antigens</subject><subject>Bioavailability</subject><subject>Clinical trials</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Drug Approval</subject><subject>Drug dosages</subject><subject>Glucagon</subject><subject>Glucose</subject><subject>Hormones</subject><subject>Humans</subject><subject>Insulin</subject><subject>Internal Medicine</subject><subject>Licenses</subject><subject>Licensing</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacotherapy</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - pharmacokinetics</subject><subject>Piperazines - pharmacology</subject><subject>Piperazines - therapeutic use</subject><subject>Plasma</subject><subject>Polypeptides</subject><subject>Urine</subject><issn>0012-6667</issn><issn>1179-1950</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kE1Lw0AQhhdRbK3-AC9S8eIlurOfWW-ltFUoeNHzskkmJSVNYrYp-O_dkCoieBiWYZ95Z3gIuQb6AJTqRy8oUzKiEEoYFckTMgbQJgIj6SkZUwosUkrpEbnwftu3RppzMgpTArTiY3K7ONSbsmj2RfU0XRat309XZZ24cjprmrY-uPKSnOWu9Hh1fCfkfbl4mz9H69fVy3y2jlKu2T7KlchcjJhIYVBBCoqjS2QmUWuJyHKXUZUwTgVnLs-MQMxTzGORxozHQvIJuR9yw9qPDv3e7gqfYlm6CuvOW9CcgxHAeEDv_qDbumurcF1PaQncxDRQMFBpW3vfYm6btti59tMCtb0_O_izwZ_t_dn-iJtjcpfsMPuZ-BYWADYAPnxVG2x_rf439Quw1njI</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>McCormack, Paul L.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20151101</creationdate><title>Evogliptin: First Global Approval</title><author>McCormack, Paul L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-f64da8eeb549e61c163eab5d5e775ee2fad06b230432afd94eefcef84c8238453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>AdisInsight Report</topic><topic>Agreements</topic><topic>Antigens</topic><topic>Bioavailability</topic><topic>Clinical trials</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - pharmacology</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Drug Approval</topic><topic>Drug dosages</topic><topic>Glucagon</topic><topic>Glucose</topic><topic>Hormones</topic><topic>Humans</topic><topic>Insulin</topic><topic>Internal Medicine</topic><topic>Licenses</topic><topic>Licensing</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacotherapy</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - pharmacokinetics</topic><topic>Piperazines - pharmacology</topic><topic>Piperazines - therapeutic use</topic><topic>Plasma</topic><topic>Polypeptides</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McCormack, Paul L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Drugs (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McCormack, Paul L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evogliptin: First Global Approval</atitle><jtitle>Drugs (New York, N.Y.)</jtitle><stitle>Drugs</stitle><addtitle>Drugs</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>75</volume><issue>17</issue><spage>2045</spage><epage>2049</epage><pages>2045-2049</pages><issn>0012-6667</issn><eissn>1179-1950</eissn><abstract>Evogliptin (Suganon™) is an orally bioavailable, selective dipeptidyl peptidase-4 (DPP-4; CD26 antigen) inhibitor being developed by Dong-A ST for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals. In October 2015, evogliptin received its first global approval in South Korea for blood glucose control in patients with type 2 diabetes mellitus. This article summarizes the milestones in the development of evogliptin leading to this first approval for type 2 diabetes mellitus.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>26541763</pmid><doi>10.1007/s40265-015-0496-5</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-6667 |
| ispartof | Drugs (New York, N.Y.), 2015-11, Vol.75 (17), p.2045-2049 |
| issn | 0012-6667 1179-1950 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1733194123 |
| source | Springer Link |
| subjects | AdisInsight Report Agreements Antigens Bioavailability Clinical trials Diabetes Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics Dipeptidyl-Peptidase IV Inhibitors - pharmacology Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Drug Approval Drug dosages Glucagon Glucose Hormones Humans Insulin Internal Medicine Licenses Licensing Medicine Medicine & Public Health Pharmacology/Toxicology Pharmacotherapy Piperazines - adverse effects Piperazines - pharmacokinetics Piperazines - pharmacology Piperazines - therapeutic use Plasma Polypeptides Urine |
| title | Evogliptin: First Global Approval |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T21%3A30%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evogliptin:%20First%20Global%20Approval&rft.jtitle=Drugs%20(New%20York,%20N.Y.)&rft.au=McCormack,%20Paul%20L.&rft.date=2015-11-01&rft.volume=75&rft.issue=17&rft.spage=2045&rft.epage=2049&rft.pages=2045-2049&rft.issn=0012-6667&rft.eissn=1179-1950&rft_id=info:doi/10.1007/s40265-015-0496-5&rft_dat=%3Cproquest_cross%3E3880080471%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c372t-f64da8eeb549e61c163eab5d5e775ee2fad06b230432afd94eefcef84c8238453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1737513980&rft_id=info:pmid/26541763&rfr_iscdi=true |